Annual Statements Open main menu

Cannabis Sativa, Inc. - Quarter Report: 2017 March (Form 10-Q)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

———————

FORM 10-Q

———————

 

x

 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

 

 ACT OF 1934

 

For the quarterly period ended: March 31, 2017

or

 

 

o

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

 

 ACT OF 1934

 

For the transition period from: _____________ to _____________

 

Commission File Number:  000-53571

 

Cannabis Sativa, Inc.

 (Exact name of registrant as specified in its charter)

 

NEVADA

 

20-1898270

(State or Other Jurisdiction

 

(I.R.S. Employer

of Incorporation)

 

Identification No.)

 

1646 W. Pioneer Blvd., Suite 120, Mesquite, Nevada  89027

(Address of Principal Executive Office) (Zip Code)

 

(702) 346-3906

(Registrant's telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

———————

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

 

 

Accelerated filer

 

Non-accelerated filer

 

 

Smaller reporting company

 

Emerging growth compamy

 

 

 

 

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

The number of shares of the issuer's Common Stock outstanding as of May 18, 2017 is 19,379,174.


Item 1.  Financial Statements.

 

CANNABIS SATIVA, INC.

 

 

 

 

 

 

 

CONSOLIDATED BALANCE SHEETS

 

 

 

 

 

Unaudited

 

March 31,

 

December 31,

 

2017

 

2016

 

 

 

 

Assets

Current Assets

 

 

 

Cash

$ 886,490   

 

$ 257,746   

Digital Currency

18,179   

 

41,191   

Accounts Receivable

2,569   

 

2,673   

Prepaid Consulting and Other Current Assets

72,743   

 

158,160   

Inventories

9,745   

 

9,128   

 

 

 

 

Total Current Assets

989,726   

 

468,898   

 

 

 

 

Property and Equipment, Net

3,696   

 

3,858   

Intangible Assets, Net

2,848,618   

 

2,940,968   

Goodwill

247,051   

 

247,051   

Deposits

41,000   

 

35,000   

Note Receivable - Related Party

15,742   

 

15,000   

 

 

 

 

Total Assets

$ 4,145,833   

 

$ 3,710,775   

 

 

 

 

 

 

 

 

Liabilities and  Stockholders' Equity

Current Liabilities:

 

 

 

Accounts Payable and Accrued Expenses

$ 187,460   

 

$ 164,258   

Stock Subscriptions Payable

63,000   

 

242,730   

Commitments and Contigencies

19,000   

 

19,000   

Due to Related Parties

451,879   

 

451,879   

 

 

 

 

Total Current Liabilities

721,339   

 

877,867   

 

 

 

 

Commitments and Contingencies

-

 

-

Stockholders' Equity:

 

 

 

Preferred stock $0.001 par value; 5,000,000 shares authorized;

 

 

 

   732,018 issued and outstanding

732   

 

732   

Common stock $0.001 par value; 45,000,000 shares authorized;

 

 

 

  19,255,796 and 18,645,021 shares issued and outstanding, respectively

19,256   

 

18,645   

Additional Paid-In Capital

64,442,265   

 

61,820,910   

Accumulated Deficit

(61,235,463)  

 

(59,226,331)  

 

 

 

 

Total Cannabis Sativa, Inc. Stockholders' Equity  

3,226,790   

 

2,613,956   

 

 

 

 

Non-Controlling Interest

197,704   

 

218,952   

 

 

 

 

Total Stockholders' Equity

3,424,494   

 

2,832,908   

 

 

 

 

Total Liabilities and Stockholders' Equity

$ 4,145,833   

 

$ 3,710,775   

 

 

 

 

The accompanying notes are an integral part of these consolidated financial statements


CANNABIS SATIVA, INC.

 

 

 

 

 

 

 

 

 

 

 

CONSOLIDATED STATEMENTS OF OPERATIONS

 

 

 

 

 

 

 

 

 

Unaudited

For the Three Months Ended March 31,

 

 

2017

 

2016

 

 

 

 

 

 

Revenues

 

 

$ 1,065   

 

$ 2,024   

 

 

 

 

 

 

Cost of Revenues

 

 

1,099   

 

579   

 

 

 

 

 

 

Gross Profit (Loss)

 

 

(34)  

 

1,445   

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

Professional fees

 

 

1,826,988   

 

230,769   

General and Administrative Expenses

 

 

180,346   

 

101,158   

 

 

 

 

 

 

Total Operating Expenses

 

 

2,007,334   

 

331,927   

 

 

 

 

 

 

Loss from Operations

 

 

(2,007,368)  

 

(330,482)  

 

 

 

 

 

 

Other (Income) and Expenses

 

 

 

 

 

Change in Fair Value of Digital Currency

 

 

23,012   

 

(13,063)  

Interest Expense

 

 

—   

 

4,056   

 

 

 

 

 

 

Total Other (Income) and Expenses

 

 

23,012   

 

(9,007)  

 

 

 

 

 

 

Loss Before Income Taxes

 

 

(2,030,380)  

 

(321,475)  

 

 

 

 

 

 

Income Taxes

 

 

—   

 

—   

 

 

 

 

 

 

Net Loss

 

 

(2,030,380)  

 

(321,475)  

 

 

 

 

 

 

Attributable to Non-Controlling Interest

 

 

(21,248)  

 

—   

 

 

 

 

 

 

Net Loss Attributable To Cannabis Sativa, Inc.

 

 

$ (2,009,132)  

 

$ (321,475)  

 

 

 

 

 

 

Net Loss per Common Share:

 

 

 

 

 

Basic & Diluted

 

 

$ (0.11)  

 

$ (0.02)  

 

 

 

 

 

 

Weighted Average Common Shares Outstanding:

 

 

 

 

 

Basic & Diluted

 

 

18,996,827   

 

17,385,947   

 

 

 

 

 

 

The accompanying notes are an integral part of these consolidated financial statements


CANNABIS SATIVA, INC.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unaudited

For the Three Months Ended March 31,

 

2017

 

 

2016

 

 

 

 

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

Net Loss

 

$ (2,030,380)  

 

 

$ (321,475)  

 

Adjustments to Reconcile Net Loss to Net Cash

 

 

 

 

 

 

 Used in Operating Activities:

 

 

 

 

 

 

Change in Fair Value of Digital Currency

 

23,012   

 

 

(13,064)  

 

Depreciation and Amortization

 

92,512   

 

 

12,986   

 

Stock Issued for Services and Amortization of Prepaids

 

1,738,417   

 

 

179,624   

 

Imputed Interest on Loans

 

—   

 

 

548   

 

Changes in assets and liabilities:

 

 

 

 

 

 

Accounts Receivable

 

104   

 

 

653   

 

Inventories

 

(617)  

 

 

(4,900)  

 

Deposits

 

(6,000)  

 

 

—   

 

Accounts Payable and Accrued Expenses

 

41,202   

 

 

80,085   

 

Due to Related Parties

 

—   

 

 

15,000   

Net Cash Used in Operating Activities:

 

(141,750)  

 

 

(50,543)  

 

 

 

 

 

 

 

Cash Flows from Investing Activities:

 

 

 

 

 

 

Advances to Related Parties

 

(742)  

 

 

(2,515)  

 

 

 

 

 

 

 

Cash Flows from Financing Activities:

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash Proceeds from Sale of Stock

 

415,136   

 

 

—   

 

Proceeds Received from Private Placement Memorandum

 

356,100   

 

 

—   

 

Proceeds from Related Parties

 

—   

 

 

56,500   

Net Cash Provided by Financing Activities:

 

771,236   

 

 

56,500   

 

 

 

 

 

 

 

NET CHANGE IN CASH

 

628,744   

 

 

3,442   

 

 

 

 

 

 

 

Cash - Beginning of Period

 

257,746   

 

 

10,356   

 

 

 

 

 

 

 

Cash - End of Period

 

$ 886,490   

 

 

$ 13,798   

 

 

 

 

 

 

 

Supplemental Disclosure of Cash Flow Activities:

 

 

 

 

 

 

Interest

 

$ —   

 

 

$ —   

 

Income taxes

 

$ —   

 

 

$ —   

 

 

 

 

 

 

 

The accompanying notes are an integral part of these consolidated financial statements


CANNABIS SATIVA, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2017 and 2016

 

 

1. Organization and Summary of Significant Accounting Policies:       

 

Nature of Corporation:

 

Ultra Sun Corp (the “Company,” “we” or “our”) was incorporated under the laws of Nevada in November 2004.  On November 13, 2013, we changed our name to Cannabis Sativa, Inc.   Our wholly-owned subsidiary Kush was acquired by us in June 2014 in exchange for shares of our common stock.  Our wholly-owned subsidiary Wild Earth Naturals, Inc. (“Wild Earth”) was acquired by us in July 2013 in exchange for shares of our common stock.  From our inception through September 30, 2013 we were engaged in the tanning salon business and operated a tanning salon in Saratoga Springs, Utah under the name “Sahara Sun Tanning.”  As a result of our acquisition of Wild Earth in July 2013, we became engaged in the herbal skin care products business.  On September 30, 2013, we sold the assets of the tanning salon business to a third party.  As a result of our acquisition of Kush in June 2014, along with our Wild Earth operations we are now engaged in the developing and promoting of natural cannabis products.  On November 2, 2015, Kush was spun out of the Company.  On August 8, 2016, the Company entered into a securities purchase agreement with iBudtender Inc. to purchase 50.1% of iBudtender Inc.

 

Basis of  Presentation:

 

The accompanying consolidated balance sheet at December 31, 2016, has been derived from audited consolidated financial statements and the unaudited consolidated financial statements as of March 31, 2017 and 2016, have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements, and should be read in conjunction with the audited consolidated financial statements and related footnotes included in our Annual report on Form 10-K for the year ended December 31, 2016 (the “2016 Annual Report”), filed with the Securites and Exchange Commission (the “SEC”).  It is management’s opinion, however, that all material adjustments (consisting of normal recurring adjustments), have been made which are necessary for a fair financial statements presentation.  The consolidated financial statements include all material adjustments (consisting of normal recurring accruals) necessary to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01.  Operating results for the three months ended March 31, 2017, are not necessarily indicative of the results of operations expected for the year ending December 31, 2017.

 

Principles of Consolidation:

 

The consolidated financial statements include the accounts of Cannabis Sativa, Inc., and its wholly owned subsidiary; Wild Earth Naturals, Inc., Hi-Brands International, Inc. and Eden Holdings LLC and its 50.1% ownership of iBudtender Inc. (the “Company”).  All significant inter-company balances have been eliminated in consolidation.

 

Method of Accounting:

 

The Company maintains its books and prepares its consolidated financial statements on the accrual basis of accounting.

 

Use of Estimates:

 

The preparation of these consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  Such management estimates include the valuation of digital currency, allowance for doubtful accounts, realizability of inventories, valuation of intangible assets, recoverability of long-lived assets and goodwill, and the valuation of equity based instruments. Actual results could differ from those estimates.  


CANNABIS SATIVA, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2017 and 2016

 

Liquidity

 

Our operations have been financed primarily through proceeds from notes payable, convertible notes payable, sale of common stock and revenue generated from sales of our products. These funds have provided us with the resources to operate our business, sell and support our products, attract and retain key personnel and add new products to our portfolio. We have experienced net losses and negative cash flows from operations each year since our inception. As of March 31, 2017, we had an accumulated deficit of approximately $61,200,000.

 

We have raised funds through the issuance of debt and the sale of common stock. We have also issued equity instruments in certain circumstances to pay for services from professionals and consultants. A total of $553,830 was raised in gross proceeds from the issuance of a private placement memorandum. A total of $356,100 was raised during the quarter ended March 31, 2017 and $197,730 was raised during the year ended December 31, 2016.

 

Accounts Receivable:

 

We estimate credit loss reserves for accounts receivable on an individual receivable basis. A specific allowance reserve is established based on expected future cash flows and the financial condition of the debtor.  We charge off customer balances in part or in full when it is more likely than not that we will not collect that amount of the balance due.  We consider any balance unpaid after the contract payment period to be past due.  At March 31, 2017 and December 31, 2016 the Company has established an allowance for doubtful accounts of $-0-.

 

Inventory:

 

Inventory cost includes those costs directly attributable to the product before sale. Inventory consists of salves, ointments, lotions, creams and balms and is carried at the lower of cost or net realizable value, using first-in, first-out method of determining cost. At March 31, 2017, there was $6,213 in raw materials and $3,532 in finished goods inventory. At December 31, 2016 the Company has $8,783 in raw materials and $345 in finished goods inventory.

 

Fixed Assets:

 

Property and equipment are recorded at cost.  Depreciation is provided for on the straight-line method over the estimated useful lives of the assets.  The average lives range from five (5) to ten (10) years.  Leasehold improvements are amortized on the straight-line method over the lesser of the lease term or the useful life. Maintenance and repairs that neither materially add to the value of the property nor appreciably prolong its life are charged to expense as incurred.  Betterments or renewals are capitalized when incurred.  

 

Fair Value of Financial Instruments:

 

The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts receivable, accounts payable, accrued liabilities, and notes payable approximate fair value given their short term nature or effective interest rates.

 

Cash:

 

For financial accounting purposes, cash and cash equivalents are considered to be all highly liquid investments purchased with an initial maturity of three (3) months or less.

 

Net Loss per Share:

 

Net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding for the period and contains no dilutive securities. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity.  Common stock equivalents from convertible notes payable and preferred stock were approximately $773,000 and $732,000at March 31, 2017 and 2016, respectively and are excluded from the calculation of diluted net loss per share because the effect is anti-dilutive.


CANNABIS SATIVA, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2017 and 2016

 

Revenue Recognition:

 

The Company recognizes revenue from product sales or services rendered when the following four revenue recognition criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the selling price is fixed or determinable, and collectability is reasonably assured.    

 

Digital Currencies Translations and Re-measurements

 

The Company accounts for digital currencies, which it considers to be an operating asset, at their initial cost and subsequently re-measures the carrying amounts of digital currencies it owns at each reporting period based on their current fair value. The changes in the fair value of digital currencies are included as a component of income or loss from operations. The Company currently classifies digital currencies as a current asset. The Company estimates the equivalency rate of hempcoins to bitcoins to USD from Coinmarketcap.com. The equivalency rate of garycoins to bitcoins to USD is estimated from C-cex.com and Coinmarketcap.com. The equivalency rate obtained from Coinmarket represents a generally well recognized quoted price in an active market for bitcoins, which market and related database are accessible to the Company on an ongoing basis.

 

Intangible Assets:

 

Intangible assets are comprised of patents, trademarks, the Company’s “CBDS.com” website domain and intellectual property rights.  The patent is being amortized using the straight-line method over its economic life, which is estimated to be twenty (20) years.  The trademarks are being amortized between 15 and 20 years. CBDS.com website is being amortized using the straight-line method over its economic life, which is estimated to be fifteen (15) years.  The intellectual property rights are being amortized using the straight-line month over its economic life, which is estimated to be between (10 - 15) years.

 

Long-Lived Assets:

 

We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. We evaluate assets for potential impairment by comparing estimated future undiscounted net cash flows to the carrying amount of the assets. If the carrying amount of the assets exceeds the estimated future undiscounted cash flows, impairment is measured based on the difference between the carrying amount of the assets and fair value. Assets to be disposed of would be separately presented in the consolidated balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group classified as held-for-sale would be presented separately in the appropriate asset and liability sections of the consolidated balance sheet, if material. During the three months ended March 31, 2017 and 2016, we did not recognize any impairment of our long-lived assets.

 

Income Taxes:

 

The Company estimates the annual tax rate based on projected taxable income for the full year and records a quarterly income tax provision in accordance with the anticipated annual rate. As the year progresses, we refine the estimates of the year’s taxable income as new information becomes available, including year-to-date financial results. This continual estimation process can result in a change to the expected effective tax rate for the year. When this occurs, the Company adjusts the income tax provision during the quarter in which the change in estimate occurs so that the year-to-date provision reflects the expected annual tax rate. Significant judgment may be required in determining the Company’s effective tax rate and in evaluating our tax positions.

 

The effective income tax rate of 0% for the three months ended March 31, 2017 and 2016 differed from the statutory rate, due primarily to net operating losses incurred by the Company in the respective periods.  For the three months ended March 31, 2017, a tax benefit of approximately $300,000would have been generated.  For the three months ended March 31, 2016 a tax benefit of approximately $48,000 would have been generated.  However, all benefits have been fully offset through an allowance account due to the uncertainty of the utilization of the net operating losses. As of March 31, 2017, the Company had net operating losses of approximately $2,000,000resulting in a deferred tax asset of approximately $300,000.  As of March 31, 2016, the Company had net operating losses of approximately $320,000 resulting in a deferred tax asset of approximately $48,000.  


CANNABIS SATIVA, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2017 and 2016

 

The Company has established a valuation allowance in the full amount of the deferred tax asset due to the uncertainty of the utilization of operating losses in future periods.

 

 Stock-Based Compensation: 

 

 Stock-based compensation is computed in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718. FASB ASC 718 requires all share-based payment to employees, including grants of employee stock options, to be recognized as compensation expense in the financial statements based on their fair values.  That expense will be recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). The Company has selected the Black-Scholes option pricing model as the most appropriate fair value method for our awards and have recognized compensation costs immediately as our awards are 100% vested.   

 

The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of FASB ASC 505-50.  The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.

 

In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement.  Stock-based compensation related to non-employees is accounted for based on the fair value of the related stock or options or the fair value of the services, whichever is more readily determinable in accordance with ASC 718.  

 

Advertising Expense:

 

Advertising costs are expensed as incurred and are included in general and adminsitrative expense in the accompanying consolidated statements of operations. Advertising costs were approximately $35,374 and $620 for the three months ended March 31, 2017 and 2016, respectively.

 

Business Combinations:

 

We account for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies, and contingent consideration at their fair values on the acquisition date. The final purchase price may be adjusted up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities acquired requires the use of estimates by management and was based upon currently available data. Examples of critical estimates in valuing certain of the intangible assets we have acquired or may acquire in the future include but are not limited to future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents and discount rates utilized in valuation estimates.

 

Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimate of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated statements of operations, financial position and cash flows in the period of the change in the estimate.


CANNABIS SATIVA, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2017 and 2016

 

 

Pending Accounting Pronouncements:

 

There have been no recent accounting pronouncements issued which are expected to have a material effect on the Company’s financial statements. Management continues to monitor and review recently issued accounting guidance upon issuance.

 

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230) – Classification of Certain Cash Receipts and Cash Payments. This ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. This ASU addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The issues addressed in this ASU that will affect us is classifying debt prepayments or debt extinguishment costs and contingent consideration payments made after a business combination. This update is effective for annual and interim periods beginning after December 15, 2017, and interim periods within that reporting period and is to be applied using a retrospective transition method to each period presented. Early adoption is permitted. The adoption of this ASU did not have a material impact on our consolidated financial position, results of operations and related disclosures and had no other impact to the accompanying condensed consolidated statement of cash flows for the three months ended March 31, 2017 and 2016.

 

In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends ASC Topic 718, Compensation - Stock Compensation. The ASU involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, forfeitures, classification of awards as either equity or liabilities and classification on the statement of cash flows. Certain of these changes are required to be applied retrospectively, while other changes are required to be applied prospectively. ASU 2016-09 is effective for public business entities for annual reporting periods beginning after December 15, 2016, and interim periods within that reporting period. Early adoption will be permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. As a result of the adoption of this ASU as of January 1, 2017, we have made an entity-wide accounting policy election to account for forfeitures when they occur. There is no cumulative-effect adjustment as a result of the adoption of this ASU as our estimated forfeiture rate prior to adoption of this ASU was 0%. The adoption of this ASU did not have a material impact on our consolidated financial statements and related disclosures.

 

In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. Current U.S. GAAP requires an entity to separate deferred income tax liabilities and assets into current and noncurrent amounts in a classified statement of financial position. To simplify the presentation of deferred income taxes, the amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this update. The amendments in this update will align the presentation of deferred income tax assets and liabilities with International Financial Reporting Standards (IFRS) and are effective for fiscal years after December 15, 2016, including interim periods within those annual periods. The adoption of this ASU as of January 1, 2017 did not have a material impact on our consolidated financial statements and related disclosures.


CANNABIS SATIVA, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2017 and 2016

 

Pending Accounting Pronouncements - continued:

 

In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. Topic 330. Inventory, currently requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out (FIFO) or average cost. An entity should measure in scope inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments in this ASU more closely align the measurement of inventory in U.S. GAAP with the measurement of inventory in IFRS. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period.

The adoption of this ASU as of January 1, 2017 did not have a material impact on our consolidated financial statements and related disclosures.

 

In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This ASU 2014-15 describes how an entity should assess its ability to meet obligations and sets rules for how this information should be disclosed in the consolidated financial statements. The standard provides accounting guidance that will be used along with existing auditing standards. The ASU 2014-15 is effective for the annual period ending after December 15, 2016. Early application is permitted. The adoption of this ASU as of January 1, 2017 did not have a material impact on our consolidated financial statements and related disclosures.

 

2.  Eden Holdings LLC

 

During the quarter ended September 30, 2014, the Company created Eden Holdings LLC.  The purpose of the entity is to hold the intellectual property of Cannabis Sativa, Inc.  As of March 31, 2017 and 2016, there has been no activity in the LLC.  

 

3.   Fair Value Measurements

 

We adopted ASC Topic 820 for financial instruments measured at fair value on a recurring basis. ASC Topic 820 defines fair value, establishes a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

 

 

· 

Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

 

· 

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

· 

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information.  These estimates involve uncertainties and cannot be determined with precision.  The carrying amounts of accounts receivable, inventory, accounts payable and accrued liabilities approximate fair value given their short term nature or effective interest rates.  We measure certain financial instruments at fair value on a recurring basis.  



CANNABIS SATIVA, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2017 and 2016

 

3.   Fair Value Measurements - continued

 

As of March 31, 2017, assets and liabilities measured at fair value on a recurring basis were as follows:

 

 

 

Total

 

Level 1

 

Level 2

 

Level 3

Assets:

 

 

 

 

 

 

 

 

Digital Currency

 

$ 18,179   

 

$ -   

 

$ 18,179   

 

$ -   

Total assets measured at fair value - unaudited

 

$ 18,179   

 

$ -   

 

$ 18,179   

 

$ -   

 

As of December 31, 2016, assets and liabilities measured at fair value on a recurring basis were as follows:

 

 

 

Total

 

Level 1

 

Level 2

 

Level 3

Assets:

 

 

 

 

 

 

 

 

Digital Currency

 

$ 41,191   

 

$ -   

 

$ 41,191   

 

$ -   

Total assets measured at fair value

 

$ 41,191   

 

$ -   

 

$ 41,191   

 

$ -   

 

4.  Hempcoins

 

At March 31, 2017 and December 31, 2016, the Company has possession of approximately 110,000,000 Hempcoins.  Hempcoins are reported as digital currency.  Every 10 Hempcoins are backed by 1 share of Rocky Mountain Inc (RMTN).  At March 31, 2017 and December 31, 2016 the value of Hempcoins was $2,375 and $14,911, respectively, computed by converting first to bitcoin and then to US Dollars. (See Note 1).  100,000,000 hempcoins were contributed to the Company in 2015 by a director with a cost basis of $4,731. Approximately 10,000,000 were earned by the Company during 2015 with a cost basis of $207.

 

5.  Garycoins

 

At March 31, 2017 and December 31, 2016, the Company has possession of 900,005,098 cryptocurrency coins named “President Johnson” trading under symbol “GARY,” which were contributed to the Company by a director during 2016 with a cost basis of $5,931.  President Johnson coins are reported as digital currency.  At March 31, 2017 and December 31, 2016 the value of these coins was estimated to be $15,804 and $26,280, respectively, computed by converting to a bitcoin value in US Dollars. (See Note 1).

 

6.  Investment in Joint Venture

 

On September 11, 2015, Hi-Brands International, Inc. a wholly owned subsidiary of the Company entered into a joint venture agreement with I.D.E.A – International Dental Emergency Alliance, LLC. (IDEA).  IDEA is the developer of a pharmacy discount card distribution and online marketing platform with access to a network of approximately 60,000 participating pharmacies through a virtual and/or physical discount card.  IDEA and the Company wish to develop, market and distribute a private label discount card and system under its proprietary brands and/or trademarks to the general public and to sub-distributors. The Company and IDEA have agreed to share all revenues 50/50 and IDEA has agreed to pay the Company 50% of a $0.50 shared fee per claim.  The claim fee will increase based upon a set schedule as claims increase.  The term of the agreement is for 3 years, but can be renewed for an additional three (3) year term periods.  IDEA is charging the Company a set up fee and as part of the agreement IDEA is expected to generate 25,000 members/cardholders in the first year.




CANNABIS SATIVA, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2017 and 2016

 

The Company entered into a convertible note payable with IDEA for payment of the $35,000 set-up fee.  The convertible note and accrued interest were convertible into shares of the Company’s common stock at a variable conversion price equal to 40% multiplied by the average of the 3 highest and 2 lowest trading days in the 10-day period preceding conversion.  In addition, the note contains an antidilution feature in which the conversion price could further adjust if the Company sells equity securities at an effective price less than the current conversion price, as defined.   The maturity date of the note was January 2, 2017. The note bore interest at 10%.  IDEA converted the note into 30,000 shares in April 2016.  In December 2016, the Company issued an additional 30,000 as compensation to IDEA, which were valued at approximately $150,000 based on the closing price on such date and recorded as interest expense.

 

6.  Investment in Joint Venture – continued

 

During the year ended December 31, 2015, the Company recorded the initial derivative liability of $83,000 based upon the following Black-Scholes option pricing model average assumptions: an exercise price of $0.92, stock price on the date of grant of $2.31, expected dividend yield of 0%, expected volatility of 179%, risk free interest rate of 0.50% and expected term of 2 years. The change in fair value during the three months ended March 31, 2016 was insignificant.

 

Upon initial valuation, the derivative liability exceeded the face value of the convertible note payable by approximately $48,000, which was recorded as a day one loss on derivative liability.  Subsequent remeasurements were based on the following assumptions at December 31, 2015 and April 20, 2016 (date of conversion): exercise prices of $0.28 and $2.05, stock price on the valuation date of $0.70 and $5.12, expected dividend yield of 0% and 0%, expected volatility of 134% and 169%, risk free interest rate of 0.50% and 0.50% and expected terms of 2 and 2 years, respectively.  Upon conversion, the Company reclassified approximately $83,000 to additional paid-in capital related to the convertible note.

 

7.  Intangibles

 

Intangible assets consisted of the following at March 31, 2017 and December 31, 2016:

 

 

Unaudtied

 

 

March 31,

December 31,

 

2017

2016

 

 

 

CBDS.com website (Cannabis Sativa)

$ 13,999   

$ 13,999   

Intellectual Property Rights (Cannabis Sativa)

2,894,250   

2,894,250   

Intellectual Property Rights (iBudtender)

400,000   

400,000   

Patents and Trademarks (Cannabis Sativa)

17,348   

17,348   

Patents and Trademarks (Wild Earth)

4,425   

4,425   

 

3,330,022   

3,330,022   

Less:  Accumulated Amortization

481,404   

389,054   

 

 

 

Net Intangible Assets

$ 2,848,618   

$ 2,940,968   

 

Amortization expense for the three months ended March 31, 2017 and 2016 was $92,350 and $12,762 respectively.  Amortization for each of the next 5 years is $355,660 annually.

 

Goodwill of $247,051 consisted of the acquisition of iBudtender (see Note 10) at March 31, 2017 and December 31, 2016, respectively.




CANNABIS SATIVA, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2017 and 2016

 

 

8.  Related Parties

 

The Company has receivedadvances from related parties and officers of the Company to cover operating expenses.  At March 31, 2017 and December 31, 2016, net amounts due to the related parties were $451,879. One of the notes payable is convertible at a fixed price of $2.42 During the three months ended March 31, 2017 and 2016, the Company has imputed interest on these notes at the rates between 5% and 8% per annum and has recorded interest expense related to these balances in the amount of $5,649 and $548, respectively.  Because the related parties do not expect the imputed interest to be repaid, the interest has been recorded as a contribution of capital.  

 

At March 31, 2017 and December 31, 2016 the Company has a note receivable from a related party in the amount of $15,742 and $15,000, respectively, which is due on demand.

 

9.  Stockholders’ Equity

 

Preferred Stock

The Company is authorized to issue up to 5,000,000 shares of preferred stock.  The Company designated and determined the rights of Series A preferred stock (“Series A”) with a par value of $0.001.  The Company is authorized to issue 5,000,000 shares of Series A.  The holders of Series A are entitled to dividends if the Company declares a dividend on common shares, have no liquidation preference, have voting rights equal to 1 vote per share, and can be converted into one share of common.

 

Common Stock

During the year ended December 31, 2016 the board of directors approved the issuance of 1,077,433 shares of common stock for services in the amount of $2,721,150.  Approximately $417,000 was recorded as prepaid consulting due to the non-forfeitable nature of the shares issued.  During the three months ended March 31, 2017, the Company amortized approximately $85,417 to professional fees in the accompanying consolidated statement of operations.

 

During the year ended December 31, 2016 the board of directors approved the issuance of 150,000 shares of common stock to purchase iBudtender Inc., with a fair value of $300,000 (see Note 10).  At March 31, 2017 and December 31, 2016, 50,000 shares have yet to be issued.

 

The Company approved a Private Placement Memorandum on October 14, 2016.  The total offering proceeds can be up to $1,500,000 by offering 625,000 of the Company’s stock at $2.40 per share. Each unit will consist of 1 (one) share of common stock and 1 (one) warrant.  Each warrant entitles the holder to purchase 1(one) common share at the exercise price of $4.00 which expire in January 2020.  The offering terminated on December 14, 2016 but can be extended for up to 60 additional days.  At March 31, 2017 and December 31, 2016, the Company had received $356,100 and $197,730, respectively, for a total of $553,830.  At March 31, 2017all the stock had been issued to investors as required, 230,775 shares common stock.  At December 31, 2016 no stock had yet been issued. Such amount was included in stock subscriptions payable in the accompanying balance sheet at December 31, 2016.

 

During the three months ended March 31, 2017 the board of directors approved the issuance of 300,000 shares of common stock for services in the amount of $1,653,000.  The fair value of the shares issued was based on the market price of the Company’s common stock on the measurement date.

 

During the three months ended March 31, 2017 a related party purchased 80,000 shares common stock for $415,136 in cash.




CANNABIS SATIVA, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2017 and 2016

 

10.  Purchase of iBudtender Inc.

 

On August 8, 2016, the Company purchased 50.1% interest in iBudtender Inc.  The Company paid iBudtender $50,000 and agreed to issue iBudtender 150,000 shares of common stock, of which 100,000 were issued at closing and 50,000 are to be issued 180 days from closing.  In exchange, iBudtender issued 5,010,000 shares of its common stock to the Company.   Since this was not a significant acquisition, the Company did not file an Amended 8K.

 

The following summarizes the transaction with iBudtender at closing on August 8, 2016:

 

Cash

$ 5,635

Intellectual Property

400,000

Goodwill

247,051

Total Assets

$ 652,686

 

 

Fair value of NCI

(239,281)

Notes Payable – Related Parties

(63,405)

 

 

Net Purchase

$ 350,000

 

In determining the fair value of the intangible assets, the Company considered, among other factors, the best use of acquired assets such as a business to consumer web portal and app, analyses of historical financial performance of the products and estimates of future performance of the products and intellectual properties acquired. The fair values of the identified intangible assets related to Intellectual Property and Goodwill and the Company has preliminarily recorded the purchase price as an intangible asset and such asset is being amortized over its estimated useful life of 10 years.  During 2014 and 2015, the Company utilized an amortization period of 20 years, but based on a change in estimate and the evolving industry, the Company is utilizing a useful life of 10 years. The purchase price allocation is subject to completion of the Company’s analysis of the fair value of the assets acquired as of the date of the acquisition. Any related adjustment is not expected to be material.  The final valuation is expected to be completed as soon as practicable but no later than one year from the closing of the transaction. The fair value of the non-controlling interest is based on the estimated fair value, net of discounts for lack of marketability and control.  The establishment of the allocation to goodwill and identifiable intangible assets requires the extensive use of accounting estimates and management judgment. The fair values assigned to the assets acquired are based on estimates and assumptions from data currently available.

 

The following table sets forth the components of identified intangible assets associated with the Acquisition and its estimated useful life:

 

 

 

Fair Value

 

Useful Life

Technology:  Website & App

$

400,000

 

15 Years

 

 

 

 

 




CANNABIS SATIVA, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2017 and 2016

 

11.  Going Concern Considerations

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As shown in the accompanying consolidated financial statements, the Company has negative working capital, has incurred operating losses since inception, and has not yet produced significant continuing revenues from operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern. Management anticipates that it will be able to raise additional working capital through the issuance of stock and through additional loans from investors.

 

The ability of the Company to continue as a going concern is dependent on its ability to raise adequate capital to fund operating losses until it is able to engage in profitable business operations. To the extent financing is not available, the Company may not be able to, or may be delayed in, developing its services and meeting its obligations. The Company will continue to evaluate its projected expenditures relative to its available cash and to evaluate additional means of financing in order to satisfy its working capital and other cash requirements. The accompanying financial statements do not reflect any adjustments that might result from the outcome of these uncertainties.

 

12.  Commitments and Contingencies

 

The Company leases an office and warehouse facility in Mesquite, Nevada that serves as the principal executive offices and provides manufacturing and warehouse space. The leased space consists of 908 square feet.  Rent expense for the three months ended March 31, 2017 and 2016 was $2,936 and $2,315, respectively.  On March 1, 2017, a new lease agreement was signed at a monthly rate of $1,392.  Lease term is for 12 (twelve) months with a renewal option available for an additional 12 (twelve) months.

 

Litigation

In the ordinary course of business, we may face various claims brought by third parties and we may, from time to time, make claims or take legal actions to assert our rights, including intellectual property disputes, contractual disputes and other commercial disputes. Any of these claims could subject us to litigation. Management believes the outcomes of currently pending claims are not likely to have a material effect on our consolidated financial position and results of operations.

 

In May 2015, a suit was brought against the Company by a subcontractor for non-payment of services.  In April 2017, the pending litigation was settled for $19,000, which the Company had accrued.

 

13.   Subsequent Events

 

Common Stock Issued for Services

During the period from April 1, 2017 through May 1, 2017, 143,169 restricted shares were issued for services.

 

Acquisition

In April 2017, the Company purchased intellectual property associated with the White Rabbit line of cannabis products, for $150,000 and 10,000 shares of the Company’s common stock




Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations.

 

Cannabis Sativa, Inc., together with its subsidiaries, are collectively referred to “Cannabis Sativa”, the “Company”, “us”, “we”, or “our”. The following information should be read in conjunction with the consolidated financial statements and notes thereto appearing elsewhere in this report. For additional context with which to understand our financial condition and results of operations, see the discussion and analysis included in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission (“SEC”) on May 5, 2017, as well as the consolidated financial statements and related notes contained therein.

 

Forward Looking Statements

 

Certain statements in this report, including information incorporated by reference, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements reflect current views about future events and financial performance based on certain assumptions. They include opinions, forecasts, intentions, plans, goals, projections, guidance, expectations, beliefs or other statements that are not statements of historical fact. Words such as “may,” “should,” “could,” “would,” “expects,” “plans,” “believes,” “anticipates,” “intends,” “estimates,” “approximates,” “predicts,” or “projects,” or the negative or other variation of such words, and similar expressions may identify a statement as a forward-looking statement. Any statements that refer to projections of our future financial performance, our anticipated growth and trends in our business, our goals, strategies, focus and plans, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results and the development of our products, are forward-looking statements.

 

Although forward-looking statements in this Quarterly Report on Form 10-Q reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include those discussed in this Quarterly Report on Form 10-Q. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q. We file reports with the SEC. You can read and copy any materials we file with the SEC at the SEC's Public Reference Room at 100 F Street, NE, Washington, DC 20549. You can obtain additional information about the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an Internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us.

 

Corporate History

 

We were incorporated under the laws of Nevada in November 2005.  We acquired a wholly-owned subsidiary named Kush, a Nevada corporation, in June 2014 in exchange for shares of our common stock.  Since November 2015, Kush has been spun off and is no longer a subsidiary of the Company.  Our wholly-owned subsidiary Wild Earth Naturals, Inc. ("Wild Earth") was acquired by us in July 2013 in exchange for shares of our common stock.  We acquired a 50.1% interest in our subsidiary iBudtender, Inc., including its wholly owned subsidiary iBudtender, LLC, a California limited liability company (collectively, “iBudtender”) in August of 2016 in exchange for cash and shares of our common stock. From our inception through September 30, 2013, we were engaged in the tanning salon business and operated a tanning salon in Saratoga Springs, Utah under the name "Sahara Sun Tanning."  As a result of our acquisition of Wild Earth in July 2013, we became engaged in the herbal skin care products business.  On September 30, 2013, we sold the assets of the tanning salon business to a third party.

 




Description of Our Business

 

We are engaged in the research, development, acquisition and licensing of specialized natural cannabis related products, including cannabis formulas, edibles, topicals, strains, recipes and delivery systems.  We also are engaged in marketing and branding within the cannabis space, including with our trademark pending “hi” brand and others. We hold a license for a proprietary cannabis lozenge delivery methodology, and a proprietary cannabis trauma cream formula.  We have recently been awarded a U.S. patent for a strain of cannabis plant named Ecuadorian Sativa (also referred to as CTS-A or CTA).  We also have U.S. patents pending on cannabis based compositions and methods of treating hypertension and a lozenge delivery system.

 

Our Strategy

 

We plan to license our intellectual property, including patents, branding and know-how to companies licensed under, and in full compliance with, state regulations applicable to cannabis businesses.   We also plan to market certain products and to control the quality of our products beginning at the formulation stage and continuing through controlled sourcing of raw ingredients, manufacturing, packaging, and labeling.  We will continue to support and prosecute our pending patents, and to develop and acquire new patents, trade secrets, trademarks and other intellectual property. In addition, we will seek new branding and licensing opportunities for our intellectual property and we will seek strategic corporate and product acquisitions.

 

Results of Operations

 

Three Months Ended March 31, 2017 Compared With Three Months Ended March 31, 2016

 

Revenue for the fiscal quarters ended March 31, 2017 and 2016 was $1,065 and $2,024, respectively. Cost of revenues for the fiscal quarters ended March 31, 2017 and 2016 was $1,099 and $579, respectively. Gross profit (loss) for the fiscal quarters ended March 31, 2017 and 2016 was $(34) and $1,445, respectively.  Net loss for the fiscal quarter ended March 31, 2017 was $2,030,380 compared to net loss of $321,475 for the fiscal quarter ended March 31, 2016.

 

Total operating expenses were $2,007,334 for the fiscal quarter ended March 31, 2017 and $331,927 for the fiscal quarter ended March 31, 2016.  The increase of $1,675,407 was due primarily to an increase of $1,596,219 in professional fees related to the development of business transactions for the Company.  The bulk of the expenses for both quarters were non-cash transactions.  In the first quarter of 2017, the primary non-cash transaction was stock issued for services in the amount of $1,653,000.  In the first quarter of 2016, the primary non-cash transaction was also stock issued for services in the amount of $179,624.  Despite the large net loss amounts for both quarters, because of non-cash transactions, the net cash used in operating activities was $141,750 for the quarter ended March 31, 2017 and $50,543 for the quarter ended March 31, 2016.

 

Liquidity and Capital Resources

 

As stated above, our operations used $141,750 in cash for the quarter ended March 31, 2017. During the same quarter, financing activities provided cash of $771,236. Cash provided by financing activities during the quarter ended March 31, 2017, came from cash proceeds from the sale of stock in the amount of $415,136 and cash proceeds from a private offering of stock in the amount of $356,100.

 

As stated above, our operations used $50,543 in cash for the quarter ended March 31, 2016. During the same quarter, financing activities provided cash of $56,500. Cash provided by financing activities during the first quarter of 2016, came from cash proceeds from related parties in the amount of $56,500.

 




The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business.  As stated above, we incurred net loss of $2,030,380 and $321,475, respectively, for the quarters ended March 31, 2017 and 2016 and had an accumulated deficit of $61,235,463 as of March 31, 2017.  The Company may seek to raise money for working capital purposes through a public offering of its equity capital or through a private placement of equity capital or convertible debt.  The Company has also issued an aggregate of 230,775 warrants which expire on January 31, 2020.  Each warrant is for the purchase of one share of common stock of the Company at the exercise price of $2.00 per share.  It will be important for the Company to be successful in its efforts to raise capital in this manner if it is going to be able to further its business plan in an aggressive manner.  Raising capital in this manner will cause dilution to current shareholders.

 

As of May 18, 2017, the Company had cash on hand of $563,824.  Much of the cash came from financing activities during the first quarter of 2017.  As a result, the Company believes it has sufficient liquidity to meet the immediate needs of our current operations.

 

Off Balance Sheet Arrangements

 

None

 

Item 3.  Quantitative and Qualitative Disclosures About Market Risk.

 

Not required.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

Under the supervision and with the participation of our management including our chief executive officer and our chief financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)) as of the end of the period covered by this report. Based upon that evaluation, our chief executive officer and our chief financial officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were not effective such that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding disclosure.

 

Based on its evaluation, our management concluded that there are material weaknesses in our internal control over financial reporting as follows: lack of timely closing of books and ability to get accounting information and schedules to our auditors in a timely manner.  A material weakness is a deficiency, or combination of control deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

 

Management identified the following material weaknesses:

 

 We have not performed a risk assessment and mapped our processes to control objectives;  

 We have not implemented comprehensive entity-level internal controls;  

 We have not implemented adequate system and manual controls;  

 We did not employ an adequate number of people to ensure a control environment that would allow for the  




accurate and timely reporting of the financial statements in accordance with GAAP; and  

 We do not have sufficient segregation of duties.  

 

Based on our evaluation under the frameworks described above, our management has concluded that our internal control over financial reporting was not effective as of March 31, 2017.  However, moving forward with the intended addition of additional staff, we believe our current framework will help remedy our material weaknesses.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 

 

 

PART II – OTHER INFORMATION

Item 1.  Legal Proceedings.

 

We are not a party to any material legal proceedings and, to the best of our knowledge, no such legal proceedings have been threatened against us.

 

Item 1A.  Risk Factors

 

Not required.

 

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds.

 

The board of directors approved a Private Placement Memorandum (“PPM”) on October 14, 2016, pursuant to which the Company would conduct a private placement of units.  The PPM offered 625,000 units at $2.40 per unit. Each unit consisted of one share of common stock and one warrant.  Each warrant entitles the holder to purchase one share of common stock at an exercise price of $2.00.  The warrants expire on January 31, 2020.  The offering terminated on January 31, 2017.  During the quarter ended March 31, 2017, the Company issued 230,775 shares of common stock and warrants subscribed for under the PPM in exchange for $553,830, of which $356,100 was received during the three months ended March 31, 2017.

 

During the quarter ended March 31, 2017, the Company issued 300,000 shares of common stock for services.  The shares had a fair value of $1,653,300.

 

During the quarter ended March 31, 2017, a related party purchased 80,000 shares of common stock for $415,136.

  

Each of the issuances of stock set forth above in this Item 2 was exempt from the registration requirements of Section 5 of the Securities Act of 1933 pursuant to Section 4(2) of the Act since the issuance of the shares did not involve any public offering.

 

Item 3.  Defaults Upon Senior Securities.

 

None.

 




Item 4.  Mine Safety Disclosures.

 

Not applicable.

 

Item 5.  Other Information.

 

None.

 

Item 6.  Exhibits. 

 

The following documents are included as exhibits to this report:

 

(a) Exhibits

 

 

Exhibit

Number

 

SEC Reference Number

 

 

 

Title of Document

 

 

 

 

 

 

 

3.1(1)

 

3

 

Articles of Incorporation

 

3.2(1)

 

3

 

Bylaws

 

31.1

 

31

 

Section 302 Certification of Principal Executive Officer

 

31.2

 

31

 

Section 302 Certification of Principal Financial Officer

 

32.1

 

32

 

SeS Section 1350 Certification of Principal Executive Officer

 

32.2

 

32

 

Se SSection 1350 Certification of Principal Financial Officer

 

101.INS(2)

 

 

 

XBRL Instance Document

 

101.SCH(2)

 

 

 

XBRL Taxonomy Extension Schema

 

101.CAL(2)

 

 

 

XBRL Taxonomy Extension Calculation Linkbase

 

101.DEF(2)

 

 

 

XBRL Taxonomy Extension Definition Linkbase

 

101.LAB(2)

 

 

 

XBRL Taxonomy Extension Label Linkbase

 

101.PRE(2)

 

 

 

XBRL Taxonomy Extension Presentation Linkbase

 

 

 

 

 

 

 

 

(1) Incorporated by reference to Exhibits 3.01 and 3.02 of the Company's Registration Statement on Form 10 filed January 28, 2009.

 (2) XBRL information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement or prospectus to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.

 




SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Cannabis Sativa, Inc. 

Date:  May 22, 2017

 

By:  /s/ Mike Gravel

Mike Gravel, Chief Executive Officer

(Principal Executive Officer)

 

 

By:  /s/ Carolyn Merrill

Carolyn Merrill, Chief Financial Officer

(Principal Financial and Accounting Officer)